Empirical Financial Services LLC d.b.a. Empirical Wealth Management Decreases Stock Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Empirical Financial Services LLC d.b.a. Empirical Wealth Management trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,228 shares of the medical research company’s stock after selling 57 shares during the quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management’s holdings in Thermo Fisher Scientific were worth $2,200,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Legacy Investment Solutions LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter valued at $26,000. Peterson Financial Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the third quarter worth about $27,000. Missouri Trust & Investment Co purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Endeavor Private Wealth Inc. bought a new position in Thermo Fisher Scientific during the 4th quarter valued at approximately $30,000. Finally, Decker Retirement Planning Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $43,000. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now owns 111,192 shares of the company’s stock, valued at $58,960,669.92. The trade was a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders sold 34,850 shares of company stock valued at $19,123,197. Company insiders own 0.34% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Sanford C. Bernstein raised Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target for the company in a research note on Friday, January 10th. Morgan Stanley reduced their price target on shares of Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. Redburn Atlantic started coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 target price on the stock. Scotiabank started coverage on Thermo Fisher Scientific in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 target price for the company. Finally, Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Four investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $648.95.

Thermo Fisher Scientific Trading Up 1.5 %

Thermo Fisher Scientific stock opened at $583.43 on Tuesday. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The business’s fifty day moving average is $533.60 and its 200 day moving average is $569.81. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. The stock has a market capitalization of $223.16 billion, a PE ratio of 36.58, a price-to-earnings-growth ratio of 3.82 and a beta of 0.76.

Thermo Fisher Scientific announced that its board has initiated a share buyback plan on Friday, November 15th that permits the company to buyback $4.00 billion in shares. This buyback authorization permits the medical research company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.78%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.